Cardiovascular MRI with ferumoxytol

J P Finn, K-L Nguyen, F Han, Z Zhou, I Salusky, I Ayad, P Hu, J P Finn, K-L Nguyen, F Han, Z Zhou, I Salusky, I Ayad, P Hu

Abstract

The practice of contrast-enhanced magnetic resonance angiography (CEMRA) has changed significantly in the span of a decade. Concerns regarding gadolinium (Gd)-associated nephrogenic systemic fibrosis in those with severely impaired renal function spurred developments in low-dose CEMRA and non-contrast MRA as well as efforts to seek alternative MR contrast agents. Originally developed for MR imaging use, ferumoxytol (an ultra-small superparamagnetic iron oxide nanoparticle), is currently approved by the US Food and Drug Administration for the treatment of iron deficiency anaemia in adults with renal disease. Since its clinical availability in 2009, there has been rising interest in the scientific and clinical use of ferumoxytol as an MR contrast agent. The unique physicochemical and pharmacokinetic properties of ferumoxytol, including its long intravascular half-life and high r1 relaxivity, support a spectrum of MRI applications beyond the scope of Gd-based contrast agents. Moreover, whereas Gd is not found in biological systems, iron is essential for normal metabolism, and nutritional iron deficiency poses major public health challenges worldwide. Once the carbohydrate shell of ferumoxytol is degraded, the elemental iron at its core is incorporated into the reticuloendothelial system. These considerations position ferumoxytol as a potential game changer in the field of CEMRA and MRI. In this paper, we aim to summarise our experience with the cardiovascular applications of ferumoxytol and provide a brief synopsis of ongoing investigations on ferumoxytol-enhanced MR applications.

Copyright © 2016. Published by Elsevier Ltd.

Figures

Figure1 (A-E)
Figure1 (A-E)
A 90 year old male patient with renal failure undergoing vascular evaluation for transcatheter aortic valve replacement (TAVR). First pass imaging with ferumoxytol (A,C) on thin maximum intensity projection (MIP) (A) and volume rendered (VR) (C) reconstructions show similar bright and uniform arterial enhancement as on steady state images (B,D,E), where arteries and veins show equal signal intensity. In E, the systemic veins have been made more transparent. Note extensive irregularity and tortuosity in the aorto-iliac vessels. This study was acquired at 3.0T.
Figure1 (A-E)
Figure1 (A-E)
A 90 year old male patient with renal failure undergoing vascular evaluation for transcatheter aortic valve replacement (TAVR). First pass imaging with ferumoxytol (A,C) on thin maximum intensity projection (MIP) (A) and volume rendered (VR) (C) reconstructions show similar bright and uniform arterial enhancement as on steady state images (B,D,E), where arteries and veins show equal signal intensity. In E, the systemic veins have been made more transparent. Note extensive irregularity and tortuosity in the aorto-iliac vessels. This study was acquired at 3.0T.
Figure 2 (A-C)
Figure 2 (A-C)
A 53 year old female with chronic, treated type A dissection and an endovascular thoracic aortic stent had ferumoxytol imaging because of severe renal impairment. Thin MIP images in A show the vascular enhancement status on first pass (left), two minutes post injection (middle) and one hour post injection. Differential enhancement of true and false (arrows) lumens is obvious on first pass, with uniform and stable enhancement of both lumens once the steady state is established. Volume rendered images of the first pass (B) and steady state (C) distribution phases show substantially similar anatomic information. Note the outline of the endovascular stent struts in the thoracic aorta. This study was acquired at 3.0T.
Figure 2 (A-C)
Figure 2 (A-C)
A 53 year old female with chronic, treated type A dissection and an endovascular thoracic aortic stent had ferumoxytol imaging because of severe renal impairment. Thin MIP images in A show the vascular enhancement status on first pass (left), two minutes post injection (middle) and one hour post injection. Differential enhancement of true and false (arrows) lumens is obvious on first pass, with uniform and stable enhancement of both lumens once the steady state is established. Volume rendered images of the first pass (B) and steady state (C) distribution phases show substantially similar anatomic information. Note the outline of the endovascular stent struts in the thoracic aorta. This study was acquired at 3.0T.
Figure 2 (A-C)
Figure 2 (A-C)
A 53 year old female with chronic, treated type A dissection and an endovascular thoracic aortic stent had ferumoxytol imaging because of severe renal impairment. Thin MIP images in A show the vascular enhancement status on first pass (left), two minutes post injection (middle) and one hour post injection. Differential enhancement of true and false (arrows) lumens is obvious on first pass, with uniform and stable enhancement of both lumens once the steady state is established. Volume rendered images of the first pass (B) and steady state (C) distribution phases show substantially similar anatomic information. Note the outline of the endovascular stent struts in the thoracic aorta. This study was acquired at 3.0T.
Figure 3
Figure 3
A 64 year old female with a pacemaker and renal impairment undergoing evaluation for TAVR placement. Pre-contrast black blood HASTE images (top row) show extensive intravascular signal due to slow flow, despite double inversion pulses. Post-ferumoxytol HASTE images (bottom row) with exactly the same parameters show complete suppression of the intravascular and intracardiac blood signal. This study was acquired at 1.5T.
Figure 4 (A,B)
Figure 4 (A,B)
An 87 year old male with aortic stenosis, sinus bradycardia and renal transplant undergoing evaluation for TAVR placement. Volume rendered images in the steady state distribution of ferumoxytol (A) display the entire aorto-iliac anatomy as well as the patent renal transplant artery and vein in the pelvis. Gated, spoiled gradient echo cine images show the aortic valve leaflets and the relationship of the left coronary artery ostium to the annulus (B).
Figure 4 (A,B)
Figure 4 (A,B)
An 87 year old male with aortic stenosis, sinus bradycardia and renal transplant undergoing evaluation for TAVR placement. Volume rendered images in the steady state distribution of ferumoxytol (A) display the entire aorto-iliac anatomy as well as the patent renal transplant artery and vein in the pelvis. Gated, spoiled gradient echo cine images show the aortic valve leaflets and the relationship of the left coronary artery ostium to the annulus (B).
Figure 5
Figure 5
A 46 year old female with end stage renal failure and liver disease with extensive venous thrombosis. Undergoing evaluation for organ transplantation. Volume rendered acquisition with steady state ferumoxytol (left and right frames) show detailed vascular anatomy of the thorax, abdomen and pelvis, including a hugely dilated left gonadal vein and pelvic varices. A CT venogram (middle frame) performed shortly prior to MRI suffers from contrast dilution with poorer vascular definition. Note the left sided venous catheter extending proximally through the occluded IVC. The MRI study was acquired at 3.0T.
Figure 6
Figure 6
A 19 month old male with stridor and no prior history of congenital heart disease. Volume rendered reconstruction from a single frame of a 4-D MUSIC acquisition (6A) from the anterior (left frame) and superior (right frame) perspective show a complete vascular ring due to a double arch, with normal cardiac chamber anatomy. Labels: RA right atrium; RV right ventricle; LV left ventricle, Ao ascending aorta; DAo descending aorta; LCCA left common carotid artery; RCCA right common carotid artery. Dynamic evaluation of the 4D MUSIC data confirmed compression of the trachea, summarized in 6B. This study was acquired at 3.0T.
Figure 6
Figure 6
A 19 month old male with stridor and no prior history of congenital heart disease. Volume rendered reconstruction from a single frame of a 4-D MUSIC acquisition (6A) from the anterior (left frame) and superior (right frame) perspective show a complete vascular ring due to a double arch, with normal cardiac chamber anatomy. Labels: RA right atrium; RV right ventricle; LV left ventricle, Ao ascending aorta; DAo descending aorta; LCCA left common carotid artery; RCCA right common carotid artery. Dynamic evaluation of the 4D MUSIC data confirmed compression of the trachea, summarized in 6B. This study was acquired at 3.0T.

References

    1. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242(3):647–649.
    1. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clinical journal of the American Society of Nephrology : CJASN. 2007;2(2):264–267.
    1. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR American journal of roentgenology. 2007;188(6):1447–1474.
    1. American College of Radiology. ACR Manual on Contrast Media (Version 10). 2015. Accessed September 1, 2015. 79–93. .
    1. Edelman RR, Sheehan JJ, Dunkle E, Schindler N, Carr J, Koktzoglou I. Quiescent-interval single-shot unenhanced magnetic resonance angiography of peripheral vascular disease: Technical considerations and clinical feasibility. Magnetic resonance in medicine : official journal of the Society of Magnetic. 2010;63(4):951–958.
    1. Miyazaki M, Sugiura S, Tateishi F, Wada H, Kassai Y, Abe H. Non-contrast-enhanced MR angiography using 3D ECG-synchronized half-Fourier fast spin echo. J Magn Reson Imaging. 2000;12(5):776–783.
    1. Brittain JH, Olcott EW, Szuba A, et al. Three-dimensional flow-independent peripheral angiography. Magnetic resonance in medicine : official journal of the Society of Magnetic. 1997;38(3):343–354.
    1. Katoh M, Buecker A, Stuber M, Gunther RW, Spuentrup E. Free-breathing renal MR angiography with steady-state free-precession (SSFP) and slab-selective spin inversion: initial results. Kidney international. 2004;66(3):1272–1278.
    1. Priest AN, Graves MJ, Lomas DJ. Non-contrast-enhanced vascular magnetic resonance imaging using flow-dependent preparation with subtraction. Magnetic resonance in medicine : official journal of the Society of Magnetic. 2012;67(3):628–637.
    1. Fan Z, Sheehan J, Bi X, Liu X, Carr J, Li D. 3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. Magnetic resonance in medicine : official journal of the Society of Magnetic. 2009;62(6):1523–1532.
    1. Hodnett PA, Ward EV, Davarpanah AH, et al. Peripheral arterial disease in a symptomatic diabetic population: prospective comparison of rapid unenhanced MR angiography (MRA) with contrast-enhanced MRA. AJR American journal of roentgenology. 2011;197(6):1466–1473.
    1. Kwon KT, Kerr AB, Wu HH, Hu BS, Brittain JH, Nishimura DG. Non-contrast-enhanced peripheral angiography using a sliding interleaved cylinder acquisition. Magnetic resonance in medicine : official journal of the Society of Magnetic. 2015;74(3):727–738.
    1. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. AJR American journal of roentgenology. 2011;196(2):W138–143.
    1. Raisch DW, Garg V, Arabyat R, et al. Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration’s Adverse Event Reporting System and review of case reports in the literature. Expert opinion on drug safety. 2014;13(1):15–23.
    1. Aran S, Shaqdan KW, Abujudeh HH. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections. Clin Radiol. 2015;70(5):466–475.
    1. Tomasian A, Salamon N, Lohan DG, Jalili M, Villablanca JP, Finn JP. Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography--feasibility study. Radiology. 2008;249(3):980–990.
    1. Habibi R, Krishnam MS, Lohan DG, et al. High-spatial-resolution lower extremity MR angiography at 3.0 T: contrast agent dose comparison study. Radiology. 2008;248(2):680–692.
    1. Nael K, Krishnam M, Nael A, Ton A, Ruehm SG, Finn JP. Peripheral contrast-enhanced MR angiography at 3.0T, improved spatial resolution and low dose contrast: initial clinical experience. Eur Radiol. 2008;18(12):2893–2900.
    1. Wang J, Yan F, Liu J, et al. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging. 2013;38(4):926–937.
    1. US Food and Drug Administration. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. 2010. Accessed January 27, 2016. .
    1. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology. 1995;196(2):481–488.
    1. Bayer. Feridex Drug Label. 2007.
    1. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging. 1997;7(1):209–214.
    1. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. Journal of X-ray science and technology. 2003;11(4):231–240.
    1. Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging. 2005;21(1):46–52.
    1. Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology. 2012;265(2):584–590.
    1. Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ. Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation. 2013;96(1):91–96.
    1. Nayak AB, Luhar A, Hanudel M, et al. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatric nephrology (Berlin, Germany). 2015;30(3):515–521.
    1. Han F, Rapacchi S, Khan S, et al. Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: A feasibility study in children. Magnetic resonance in medicine : official journal of the Society of Magnetic. 2015. Oct;74(4):1042–1049.
    1. Ruangwattanapaisarn N, Hsiao A, Vasanawala SS. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol. 2015. Jun;45(6):831–839.
    1. Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015. Apr;41(4):884–898.
    1. Walker JP, Nosova E, Sigovan M, et al. Ferumoxytol-Enhanced Magnetic Resonance Angiography is a Feasible Method for the Clinical Evaluation of Lower Extremity Arterial Disease. Annals of vascular surgery. 2015;29(1):63–68.
    1. Yilmaz A, Rosch S, Yildiz H, Klumpp S, Sechtem U. First multiparametric cardiovascular magnetic resonance study using ultrasmall superparamagnetic iron oxide nanoparticles in a patient with acute myocardial infarction: new vistas for the clinical application of ultrasmall superparamagnetic iron oxide. Circulation. 2012;126(15):1932–1934.
    1. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19(8):1599–1605.
    1. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–915.
    1. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical journal of the American Society of Nephrology : CJASN. 2009;4(2):386–393.
    1. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clinical therapeutics. 2014;36(1):70–83.
    1. Takeda. Rienso. 2012. Accessed January 23, 2016. .
    1. European Medicines Agency. Rienso. 2015. Accessed January 23, 2016. .
    1. Ning P, Zucker EJ, Wong P, Vasanawala SS. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults. Magnetic resonance imaging. 2016;34(2):152–158.
    1. Muehe AM, Feng D, von Eyben R, et al. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Invest Radiol. 2015.
    1. Klenk C, Gawande R, Uslu L, et al. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. The Lancet Oncology. 2014;15(3):275–285.
    1. Bashir MR, Mody R, Neville A, et al. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging. 2014;40(1):113–118.
    1. Alam SR, Shah AS, Richards J, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circulation Cardiovascular imaging. 2012;5(5):559–565.
    1. Thompson EM, Guillaume DJ, Dosa E, et al. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. Journal of neuro-oncology. 2012;109(1):105–114.
    1. Hassan N, Cahill J, Rajasekaran S, Kovey K. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series. The Annals of pharmacotherapy. 2011;45(12):e63.
    1. D’Arceuil H, Coimbra A, Triano P, et al. Ferumoxytol enhanced resting state fMRI and relative cerebral blood volume mapping in normal human brain. Neuroimage. 2013;83:200–209.
    1. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Advanced drug delivery reviews. 2006;58(14):1471–1504.
    1. Aregger F, Wenaweser P, Hellige GJ, et al. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2009;24(7):2175–2179.
    1. Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. European heart journal. 2010;31(7):865–874.
    1. Barbash IM, Ben-Dor I, Dvir D, et al. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. American heart journal. 2012;163(6):1031–1036.
    1. Goebel N, Baumbach H, Ahad S, et al. Transcatheter aortic valve replacement: does kidney function affect outcome? Ann Thorac Surg. 2013;96(2):507–512.
    1. Sinning JM, Ghanem A, Steinhauser H, et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovascular interventions. 2010;3(11):1141–1149.
    1. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney international. 2005;68(1):14–22.
    1. Yamamoto M, Hayashida K, Mouillet G, et al. Renal function-based contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation. JACC Cardiovascular interventions. 2013;6(5):479–486.
    1. Powell AJ. SCMR Survey of Centers Performing CMR in Pediatric/Congenital Heart Disease. 2014.
    1. Sorensen TS, Korperich H, Greil GF, et al. Operator-independent isotropic three-dimensional magnetic resonance imaging for morphology in congenital heart disease: a validation study. Circulation. 2004;110(2):163–169.
    1. Fenchel M, Greil GF, Martirosian P, et al. Three-dimensional morphological magnetic resonance imaging in infants and children with congenital heart disease. Pediatr Radiol. 2006;36(12):1265–1272.
    1. Seeger A, Fenchel MC, Greil GF, et al. Three-dimensional cine MRI in free-breathing infants and children with congenital heart disease. Pediatr Radiol. 2009;39(12):1333–1342.
    1. Cheng JY, Hanneman K, Zhang T, et al. Comprehensive motion-compensated highly accelerated 4D flow MRI with ferumoxytol enhancement for pediatric congenital heart disease. J Magn Reson Imaging. 2015.
    1. Zhou Z, Han F, Rapacchi S, Ayad I, Salusky I, Plotnik A, Finn JP, Hu P. Accelerated Four-dimensional, multiphase, steady-state imaging with Contrast Enhancement (MUSIC) using Parallel Imaging and Compressed Sensing. In Proceedings of the 23rd Annual Meeting of ISMRM. Toronto, Ontario, Canada 2015. p. 180.
    1. Han F, Zhou Z, Han ES, Finn JP, Hu P. Cardiac and respiratory self-gated 4D multi-phase steady-state imaging with ferumoxytol contrast (MUSIC). Journal of Cardiovascular Magnetic Resonance. 2016;18(Suppl 1):O51.
    1. Hope MD, Hope TA, Zhu C, et al. Vascular Imaging With Ferumoxytol as a Contrast Agent. AJR American journal of roentgenology. 2015;205(3):W366–373.
    1. Corwin MT, Fananapazir G, Chaudhari AJ. MR Angiography of Renal Transplant Vasculature with Ferumoxytol:: Comparison of High-Resolution Steady-State and First-Pass Acquisitions. Academic radiology. 2015.
    1. Florian A, Ludwig A, Rosch S, et al. Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction - A cardiovascular magnetic resonance (CMR) study. International journal of cardiology. 2014.
    1. Yilmaz A, Dengler MA, van der Kuip H, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. European heart journal. 2013;34(6):462–475.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться